Dmitri I Loukinov

7375206, May 20, 2008

Feb 21, 2003

10/505377

Victor V. Lobanenkov - Rockville MD, US
Dmitri I. Loukinov - Germantown MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

C07H 21/04
C07H 21/02
C12Q 1/68

536 235, 536 231, 435 6

An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a vector comprising such an isolated or purified nucleic acid molecule; a cell comprising such a vector; an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; a cell line that produces a monoclonal antibody that is specific for an aforementioned isolated or purified polypeptide molecule; and the monoclonal antibody produced by the cell line; methods of diagnosing a cancer or a predisposition to a cancer in a male or female mammal; a method of prognosticating a cancer in a mammal; a method of assessing the effectiveness of treatment of a cancer in a mammal; a method of treating a mammal prophylactically or therapeutically for a cancer, and a composition comprising a carrier and an inhibitor of BORIS.

7785814, Aug 31, 2010

Sep 21, 2005

11/575732

Victor V. Lobanenkov - Rockville MD, US
Dmitri Loukinov - Germantown MD, US
Svetlana Pack - N. Potomac MD, US

The United States of America as represented by the Department of Health and Human Services - Washington DC

G01N 33/574

435 723, 435 721

The invention provides a method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising detecting antibodies to BORIS in a sample obtained from the mammal. The invention also provides BORIS polypeptides as well as compositions and kits comprising the BORIS polypeptides and methods of using the same. The invention further provides a method of inducing an immune response in a mammal using BORIS polypeptides.

8440415, May 14, 2013

May 23, 2012

13/478779

Victor V. Lobanenkov - Rockville MD, US
Elena Pugacheva - Germantown MD, US
Dmitri Loukinov - Germantown MD, US

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

G01N 33/53

435 71, 436518

A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same.

8206933, Jun 26, 2012

Aug 30, 2007

12/439063

Victor V. Lobanenkov - Rockville MD, US
Elena Pugacheva - Germantown MD, US
Dmitri Loukinov - Germantown MD, US

The United States of America, as represented by the Department of Health and Human Services - Washington DC

G01N 33/53

435 71, 436518

A method of detecting a proliferative disease, such as a disease associated with the abnormal expression of BORIS, in a mammal comprising testing for the expression of a BORIS isoform in the tissue of a mammal that does not express BORIS in the absence of disease, as well as a method of treating or preventing such a disease, isolated or purified BORIS isoform polypeptides and nucleic acids, and kits and arrays comprising same.

6387888, May 14, 2002

Sep 30, 1998

09/164034

Milcho S. Mincheff - Rockville MD
Dmitri I. Loukinov - Germantown MD
Serguei Zoubak - Germantown MD

American Foundation for Biological Research, Inc. - Rockville MD

A61K 4800

514 44, 4353201, 435325, 536 231, 536 235

DNA constructs for truncated forms of cancer-specific or cancer associated antigens are included in plasmid or viral expression vectors. The rationale to use constructs for truncated and not for full-size molecules is to eliminate side effects (toxicity, signal transduction etc. ) arising from expressed proteins and/or, in cases where such molecules are expressed on the membrane, secreted, or released in the extracellular environment, to prevent formation of antibodies against them. The extracellular portion of the human prostate specific membrane specific antigen (XC-PSMA) has been cloned. Patients were treated either by injection of DNA coding for XC-PSMA in a mammalian expression vector under the CMV promoter or/and by a replication-defective adenoviral vector (Ad5)hat contains an expression cassette for the XC-PSMA. In a third method dendritic cells are isolated from a patient and are treated by exposure to the plasmid or adenovirus used in the previous two treatments. The dendritic cells are then injected into the patient.